Aim immunotech announces positive data from phase 2a study evaluating ampligen® as a component of a chemokine modulatory (ckm) regimen for the treatment of colorectal cancer metastatic to the liver

Primary endpoint of the study was met, evidenced by increased cd8a expression post-treatment (p=0.046)

AIM Ratings Summary

AIM Quant Ranking